ASHLEIGH EBRENEYIN: Open Payments
NPI 1235872375 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,311 in 101 payments from 21 companies in 2025. Trend: 2023 $1,260 · 2024 $1,613 · 2025 $2,311
Food & beverage: $2,311
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $384 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $312 |
| PFIZER INC. | 10 | $248 |
| QOL Medical, LLC | 8 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $204 |
| Lilly USA, LLC | 4 | $125 |
| Janssen Biotech, Inc. | 4 | $111 |
| GENZYME CORPORATION | 4 | $109 |
| Ipsen Biopharmaceuticals, Inc | 4 | $102 |
| Madrigal Pharmaceuticals | 5 | $99 |
Products named: XIFAXAN, Sucraid, VELSIPITY, RINVOQ, LINZESS, DUPIXENT, OMVOH, TREMFYA.
Industry payments across DC — which companies pay providers there.
